Brainstorm Cell Therapeutics Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-30. Between them they name 3 people, with 1 appointment and 2 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Peter Pitts, Chief Strategic Regulatory Officer
On July 24, 2026, the Board of Directors (the " Board ") of Brainstorm Cell Therapeutics Inc. (the " Company ") appointed Peter Pitts, a member of the Board, as Executive Chairman of the Board and Chief Strategic Regulatory Officer.
Departing: Consultant Jacob Frenkel, Chairman of the Board
Executive Chairman Resignation and Transition to Consultant Jacob Frenkel, Ph.D., resigned as Chairman of the Board and as a director on July 24, 2026.
Departing: Ibrahim B. Dagher, Chief Medical Officer
On July 26, 2026, Ibrahim B. Dagher, MD, Executive Vice President and Chief Medical Officer of the Company, resigned from his positions with the Company, effective immediately.
Reported
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
Find people with the same kind of experience as the Chief Strategic Regulatory Officer at Brainstorm Cell Therapeutics Inc., with the record behind each one.
Find candidates like Chief Strategic Regulatory Officer at Brainstorm Cell Therapeutics Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Brainstorm Cell Therapeutics Inc. is in the news or changes leadership.
Get an alert when Brainstorm Cell Therapeutics Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Brainstorm Cell Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.